Johnson & Johnson said Wednesday that its Janssen
Pharmaceutical segment plans to file for regulatory approval of at
least 10 new drugs by 2019, each with the potential to exceed $1
billion in revenue.
The company also said it plans more than 40 line extensions of
existing and new medicines.
"We look forward to continuing to drive above-industry growth
with our current in-market portfolio and next wave of medicines,"
said Joaquin Duato, world-wide pharmaceuticals chairman. "We are
working with our partners to advance the innovative products in our
pipeline and to deliver significant benefits to patients."
J&J said late-stage products expected to drive growth in the
next several years include daratumumab for multiple myeloma,
sirukumab for rheumatoid arthritis, and guselkumab for
psoriasis.
The company meets with industry analysts Wednesday.
Shares, down 0.6% this year, rose 0.5% to $104.50 in premarket
trading.
Write to Lisa Beilfuss at lisa.beilfuss@wsj.com
Access Investor Kit for Johnson & Johnson
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US4781601046
Subscribe to WSJ: http://online.wsj.com?mod=djnwires